Renal Cell Carcinoma

The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

James A. Brown, MD, Professor of Urology, Professor of Biomedical Engineering, University of Iowa Carver College of Medicine, discusses an analysis of cell cycle progression scores in patients with clear cell renal cell carcinoma (ccRCC) to evaluate its prognostic value.

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.

Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma

Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in kidney cancer and developing biomarkers for anti-PD-L1 agents.

According to a retrospective analysis of the phase III COMPARZ trial, high tumor expression of the protein PD-L1 (programmed cell death 1 ligand 1) is independently associated with shorter overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).

Most medical oncologists in the United States would opt for an mTOR (mammalian target of rapamycin) inhibitor as second-line therapy for patients with metastatic clear cell renal cell carcinoma (mccRCC).

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.

The use of angiotensin system inhibitors (ASIs) may significantly improve survival outcomes in patients with metastatic renal cell carcinoma (mRCC), according to a vast, pooled retrospective analysis.

A research team at Cold Spring Harbor Laboratory in New York has succeeded in identifying the most common genetically altered genes and the major oncogenic drivers in hepatitis B virus-associated hepatocellular carcinoma (HCC).

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma (RCC). The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

The development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma (RCC) has led to improved survival rates for patients.

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).

PD-L1 expression in tumors is a candidate molecular marker warranting further investigation as a means to select patients for immunotherapy with an anti PD-1 antibody

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

AGS-003, an investigational autologous dendritic cell vaccine, successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma (mRCC), according to an analysis presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer.